REDWOOD CITY, Calif., June 3, 2026 /PRNewswire/ -- Liftoff Mobile, Inc. ("Liftoff"), a global leader in performance marketing and monetization solutions for the app...
BROOMFIELD, Colo., June 4, 2026 /PRNewswire/ -- Quantinuum Inc. ("Quantinuum") today announced the pricing of the upsized initial public offering of 28,000,000 shares of its...
This news release contains forward-looking statements. For a description of the related risk factors and assumptions, please see the section entitled "Caution Concerning Forward-Looking...
DALLAS, TX, June 03, 2026 (GLOBE NEWSWIRE) -- Long Table Growth Corp. (the “Company”) today announced the pricing of its initial public offering of 15,000,000 units at a price of $10.00 per unit. The units are expected to commence trading on The Nasdaq Global Market (“Nasdaq”) under the ticker symbol “LTGRU” beginning on June 4, 2026. Each unit sold in the offering consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. Only whole warrants will be exercisable. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “LTGR” and “LTGRW,” respectively. The offering is expected to close on June 5, 2026, subject to customary closing conditions.
Starting in June, guests can grab select oven-ready pizzas for $8.99* and enjoy fresh-from-the-oven pizza nights all summer long.VANCOUVER, Wash., June 3, 2026 /PRNewswire/...
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, June 3, 2026 /CNW/ - Principal Technologies Inc. (TSXV: PTEC) (FWB:...
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ChampionX (CHX) To Contact Him Directly To Discuss Their Options
Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.
BEIJING, June 3, 2026 /PRNewswire/ -- Jianzhi Education Technology Group Company Limited (NASDAQ: JZ) (the "Company" or "Jianzhi") today announced the closing of its...
New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan